The Biotech Industry has continued to outpace the broader markets in 2013. The iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and the SPDR S&P Biotech ETF (NYSEARCA: XBI) have posted gains of approximately 53.0 and 49.0 percent, respectively, more than 2.5 times the S&P 500 Index’s gain of 19.0 percent. The red hot biotech market has already caused more biotech companies to go public in the first half of 2013, than all of 2012. Here is how some biotech companies reacted Thursday:
Cancer Genetics Inc. (NASDAQ: CGIX) shares traded in the range of $16.65 to $22.85 Friday before settling to close at $21.00, an increase of 29.23 percent. The stock appears to have some support at the $16.35, $14.33 and $12.84 levels. Shares of Cancer Genetics have gained approximately 130.0 percent in 2013.
More information on Cancer Genetics and access to the free equity report can be found at:
Rockwell Medical Inc. (NASDAQ: RMTI) shares traded in the range of $9.06 to $10.85 Friday before settling to close at $10.77, an increase of 16.94 percent. The stock appears to be facing some resistance at $10.77 with some support at the $10.11 and $9.68 levels. Shares of Rockwell Medical have gained approximately 33.0 percent in 2013.
More information on Rockwell Medical and access to the free equity report can be found at:
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) shares traded in the range of $6.25 to $6.72 Friday before settling to close at $6.60, an increase of 6.45 percent. The stock appears to be facing some resistance at the $6.77 and $6.99 levels with some support at $6.49. Shares of Sucampo Pharmaceuticals have gained approximately 35.0 percent in 2013.
More information on Sucampo Pharmaceuticals and access to the free equity report can be found at:
Ventrus Biosciences Inc. (NASDAQ: VTUS) shares traded in the range of $2.90 to $3.13 Friday before settling to close at $3.12, an increase of 10.64 percent. The stock appears to be facing some resistance at $3.34 with some support at the $2.98 and $2.75 levels. Shares of Ventrus Biosciences have gained approximately 44.0 percent in 2013.
More information on Ventrus Biosciences and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals
Leave a comment...